Browse News

Found 1,112 articles

• Aurion Biotech Receives Approval from Japan’s PMDA for New Drug Application

  3/23/2023

  Aurion Biotech announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency for its novel cell therapy, Vyznova™, for the treatment of bullous keratopathy of the cornea.

• Sight Sciences Reports Fourth Quarter and Full Year 2022 Financial Results

  3/13/2023

  Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”) today reported financial results for the fourth quarter and year ended December 31, 2022 and issued financial guidance for the year ending December 31, 2023.

• Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/3/2023

  Kala Pharmaceuticals, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

• Alcon Reports Fourth Quarter and Full Year 2022 Results

  2/27/2023

  Alcon, the global leader in eye care, reported its financial results for the three and twelve months ended December 31, 2022.

• Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer

  2/27/2023

  Lyra Therapeutics, Inc. today announced the appointment of John Bishop, Ph.D., as Chief Technology Officer, effective February 27, 2023.

• Clearside Biomedical Announces Leadership Team Update

  2/6/2023

  Clearside Biomedical, Inc. today announced that its Chief Medical Officer and Chief Development Officer, Thomas A. Ciulla, M.D., M.B.A., will transition to the role of Chief Medical Advisor-Retina for Clearside and step down from his full-time position, effective February 17, 2023.

• Outlook Therapeutics® Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence

  1/19/2023

  Outlook Therapeutics, Inc. announced the appointments of Surendra Sharma, MD, as Senior Vice President, Medical Affairs, and Glen Olsheim as Executive Director, Commercial Excellence.

• Mallinckrodt Announces Appointment of Dr. Peter Richardson, MRCP, as Chief Scientific Officer

  1/12/2023

  Mallinckrodt plc today announced that Dr. Peter Richardson, B.Med.Sci., BM, BS, MRCP (UK) has been appointed Executive Vice President and Chief Scientific Officer, effective January 12, 2023.

• ADC Therapeutics Appoints Jose Carmona as Chief Financial Officer

  12/19/2022

  ADC Therapeutics SA (NYSE: ADCT) today announced the appointment of Jose “Pepe” Carmona as Chief Financial Officer (CFO), effective December 19, 2022.

• Aurion Biotech Appoints Jonathan Sparks, JD, PhD as Chief Legal Officer

  12/7/2022

  Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Dr. Jonathan Sparks as chief legal officer.

• Aurion Biotech Expands Its Leadership Team

  11/30/2022

  Aurion Biotech today announced it has appointed Sherita Hall as vice president, clinical operations and Sterling Chung as vice president, global regulatory affairs.

• Ophthalmic Drugs Market Demand and Growth Analysis with Forecast up to 2030

  11/23/2022

  According to Nova one advisor, the global Ophthalmic Drugs market size is expected to hit around USD 67.1 billion by 2030 from valued at USD 33.9 billion in 2021 and growing at a CAGR of 7.40% from 2022 to 2030.

• Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business

  11/22/2022

  Alcon, the global leader in eye care dedicated to helping people see brilliantly, announced that it has completed its acquisition of Aerie Pharmaceuticals, Inc.

• Alcon Reports Third Quarter 2022 Results

  11/15/2022

  Alcon (SIX/NYSE:ALC), the global leader in eye care, reported its financial results for the three and nine months ended September 30, 2022.

• Alcon Elevates Dry Eye Care in Canada with Latest Innovation: Systane iLux2 MGD Thermal Pulsation System

  11/15/2022

  Alcon today announced the Canadian launch of its latest innovation to treat patients with dry eye: the Systane MD iLux 2MD  Meibomian Gland Dysfunction (MGD) Thermal Pulsation System.

• Respiratory Virus Vaccines Market Size to Hit Around US$ 14.6 Bn by 2030

  11/10/2022

  According to Vision Research Reports, the global respiratory virus vaccines market size is projected to hit around US$ 14.6 billion by 2030 from US$ 3.2 billion in 2020, growth is expanding at a CAGR of 8.1% from 2021 to 2030.

• Kala Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

  11/8/2022

  Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.

• Ophthalmic Drugs Market Size, Share, Trends, Growth, Report 2021-2030

  11/8/2022

  The global Ophthalmic Drugs market size is expected to be worth around US$ 70.5 billion by 2030, according to a new report by Vision Research Reports.

• Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results

  11/3/2022

  Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today reports financial results for the third quarter ended September 30, 2022.

• Kala Pharmaceuticals Announces Appointment of Marjan Farid, M.D., to its Board of Directors

  11/1/2022

  Kala Pharmaceuticals, Inc. today announced the appointment of Marjan Farid, M.D., to its Board of Directors.